Clinical Trials Logo

Clinical Trial Summary

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Friedreich's Ataxia and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Clinical Trial Description

An ataxia is neurological disorder of balance and coordination resulting from dysfunctions of the cerebellum. Friedreich's ataxia (FRDA) is most common ataxia in white population, with an estimated prevalence of 2-4 cases per 100,000 individuals. With an average age of onset of 10-15 years, the disease is characterized by dysarthria, deep sensory loss, hypertrophic cardiomyopathy, spinocerebellar ataxia, pyramidal weakness, diabetes mellitus, and skeletal abnormalities. FRDA is an autosomal recessive disorder caused by pathogenic variant/s in the FXN gene, which encodes the mitochondrial protein frataxin. In 98% of cases these are homozygous guanine-adenine-adenine (GAA) triplet repeat expansions in the first intron of the FXN gene. The remaining cases are compound heterozygotes for a GAA repeat expansion plus a FXN point mutation or deletion. GAA repeat expansions suppress transcription of the FXN gene, leading to frataxin deficiency. Until now there is no FDA-approved therapy for FRDA, but potential agents for treatment are in developing phases. As such, especially antioxidants like idebenone are tested in clinical trials as FRTA medication, whereas another study identified p38 inhibitors as potential therapeutic agents. Various clinical rating scales including the Scale for the Assessment and Rating of Ataxia (SARA), Friedreich's Ataxia Rating Scale (FARS), and the International Cooperative Ataxia Rating Scale (ICARS) have been used as trial endpoints in FRDA, but these measurements have limited sensitivity to disease progression over 12 months. Furthermore, there are no validated, objective central or peripheral nervous system biomarkers of disease progression for use in clinical trials as intermediate endpoints. It is the goal of the BioFridA study to identify, validate, and monitor FRDA biomarker/s. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04548921
Study type Observational
Source CENTOGENE GmbH Rostock
Status Enrolling by invitation
Start date July 1, 2020
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05358964 - Family Health Histories: Creating a Culturally Tailored Tool to Reduce Health Disparities in the Black Community N/A
Recruiting NCT06183138 - Multicenter Analysis of Genomic and Metabolic Data of Neonatal Genetic Diseases
Recruiting NCT06107400 - Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease Early Phase 1
Completed NCT00001466 - Study of Clinical and Molecular Manifestations of Genetic Disorders N/A
Active, not recruiting NCT04428710 - Assessment Psychological Distress for Cancer Heredity Test
Recruiting NCT04531696 - UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research N/A
Completed NCT01343953 - Cord Blood Transplantation in Severe Aplastic Anemia Phase 2
Enrolling by invitation NCT05721326 - Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition N/A
Recruiting NCT06330441 - Pancreatic Cancer Screening in a Population at High Risk N/A
Completed NCT02416440 - Durban Diabetes Study:A Study of the Epidemiology of Diabetes Mellitus in Urban South Africans of African Descent (DDS) Phase 0
Recruiting NCT05587439 - Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Withdrawn NCT04531878 - BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases Phase 2/Phase 3
Completed NCT02917070 - Parental Consanguinity and Family History of Kidney Disease in Turkish Kidney Disease Population N/A
Active, not recruiting NCT01645904 - A Social Media Approach to Improve Genetic Risk Communication Phase I
Recruiting NCT05161169 - Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants N/A
Recruiting NCT06157983 - Evaluation of Cascade Screening for Elevated Lipoprotein(a)
Active, not recruiting NCT04528498 - Embryo Health Study
Completed NCT05453474 - Cell-based Non-invasive Prenatal Testing as an Alternative to Invasive Chorionic Villus Sampling N/A
Terminated NCT00314691 - Development of New Prenatal Diagnostic Tests From Maternal Blood N/A